BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Increases Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 43.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 203,401 shares of the medical research company’s stock after buying an additional 61,710 shares during the period. Thermo Fisher Scientific accounts for 0.6% of BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s portfolio, making the stock its 27th biggest position. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp owned approximately 0.05% of Thermo Fisher Scientific worth $105,815,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TMO. Vanguard Group Inc. raised its stake in Thermo Fisher Scientific by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 33,249,575 shares of the medical research company’s stock worth $17,297,426,000 after buying an additional 196,864 shares in the last quarter. Capital World Investors raised its position in shares of Thermo Fisher Scientific by 1.1% in the 4th quarter. Capital World Investors now owns 9,430,120 shares of the medical research company’s stock worth $4,905,812,000 after acquiring an additional 104,343 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Thermo Fisher Scientific by 2.6% in the 4th quarter. Geode Capital Management LLC now owns 7,857,385 shares of the medical research company’s stock valued at $4,075,540,000 after purchasing an additional 197,442 shares during the period. Norges Bank purchased a new stake in Thermo Fisher Scientific in the fourth quarter worth $3,149,754,000. Finally, Northern Trust Corp raised its holdings in Thermo Fisher Scientific by 13.2% in the fourth quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company’s stock worth $2,034,107,000 after purchasing an additional 455,004 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling

In other news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president now owns 23,167 shares of the company’s stock, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the sale, the senior vice president now owns 10,816 shares of the company’s stock, valued at approximately $5,759,736.32. This represents a 25.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 14,075 shares of company stock valued at $7,305,942. Corporate insiders own 0.33% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of research reports. Royal Bank of Canada dropped their target price on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. StockNews.com downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Friday, April 25th. Wells Fargo & Company cut their price target on Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating on the stock in a research note on Thursday, April 24th. UBS Group dropped their target price on Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating on the stock in a report on Thursday, April 24th. Finally, Robert W. Baird lowered their price target on Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. Five analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $607.43.

Thermo Fisher Scientific Trading Down 0.1%

Thermo Fisher Scientific stock opened at $413.47 on Wednesday. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 12-month low of $390.50 and a 12-month high of $627.88. The firm has a market capitalization of $156.08 billion, a price-to-earnings ratio of 25.01, a P/E/G ratio of 2.99 and a beta of 0.82. The firm has a 50 day moving average of $449.99 and a 200 day moving average of $508.22.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company had revenue of $10.36 billion for the quarter, compared to analysts’ expectations of $10.23 billion. During the same quarter in the previous year, the company earned $5.11 EPS. Thermo Fisher Scientific’s revenue for the quarter was up .2% on a year-over-year basis. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.